These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22666496)

  • 1. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.
    Shiffman D; Trompet S; Louie JZ; Rowland CM; Catanese JJ; Iakoubova OA; Kirchgessner TG; Westendorp RG; de Craen AJ; Slagboom PE; Buckley BM; Stott DJ; Sattar N; Devlin JJ; Packard CJ; Ford I; Sacks FM; Jukema JW
    PLoS One; 2012; 7(5):e38240. PubMed ID: 22666496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
    Postmus I; Johnson PC; Trompet S; de Craen AJ; Slagboom PE; Devlin JJ; Shiffman D; Sacks FM; Kearney PM; Stott DJ; Buckley BM; Sattar N; Ford I; Westendorp RG; Jukema JW
    Atherosclerosis; 2014 Jul; 235(1):58-64. PubMed ID: 24816038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
    Iakoubova OA; Tong CH; Rowland CM; Kirchgessner TG; Young BA; Arellano AR; Shiffman D; Sabatine MS; Campos H; Packard CJ; Pfeffer MA; White TJ; Braunwald E; Shepherd J; Devlin JJ; Sacks FM
    J Am Coll Cardiol; 2008 Jan; 51(4):435-43. PubMed ID: 18222353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
    Iakoubova OA; Tong CH; Chokkalingam AP; Rowland CM; Kirchgessner TG; Louie JZ; Ploughman LM; Sabatine MS; Campos H; Catanese JJ; Leong DU; Young BA; Lew D; Tsuchihashi Z; Luke MM; Packard CJ; Zerba KE; Shaw PM; Shepherd J; Devlin JJ; Sacks FM
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2763-8. PubMed ID: 17008591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
    Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants in the KIF6 region and coronary event reduction from statin therapy.
    Li Y; Sabatine MS; Tong CH; Ford I; Kirchgessner TG; Packard CJ; Robertson M; Rowland CM; Bare LA; Shepherd J; Devlin JJ; Iakoubova OA
    Hum Genet; 2011 Jan; 129(1):17-23. PubMed ID: 20886236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.
    Maitland-van der Zee AH; Peters BJ; Lynch AI; Boerwinkle E; Arnett DK; Cheng S; Davis BR; Leiendecker-Foster C; Ford CE; Eckfeldt JH
    Pharmacogenet Genomics; 2009 May; 19(5):338-44. PubMed ID: 19415820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy.
    Li Y; Iakoubova OA; Shiffman D; Devlin JJ; Forrester JS; Superko HR
    Am J Cardiol; 2010 Oct; 106(7):994-8. PubMed ID: 20854963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
    Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
    Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
    Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.
    Trompet S; de Craen AJ; Postmus I; Ford I; Sattar N; Caslake M; Stott DJ; Buckley BM; Sacks F; Devlin JJ; Slagboom PE; Westendorp RG; Jukema JW;
    BMC Med Genet; 2011 Oct; 12():131. PubMed ID: 21977987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
    Polisecki E; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Blauw GJ; Westendorp RG; de Craen AJ; Trompet S; Buckley BM; Murphy MB; Ordovas JM; Schaefer EJ;
    Atherosclerosis; 2008 Sep; 200(1):95-101. PubMed ID: 18262190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.
    Drewes YM; Poortvliet RK; Blom JW; de Ruijter W; Westendorp RG; Stott DJ; Blom HJ; Ford I; Sattar N; Wouter Jukema J; Assendelft WJ; de Craen AJ; Gussekloo J
    J Am Geriatr Soc; 2014 Feb; 62(2):213-21. PubMed ID: 24447238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
    Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
    Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
    Sabatine MS; Ploughman L; Simonsen KL; Iakoubova OA; Kirchgessner TG; Ranade K; Tsuchihashi Z; Zerba KE; Long DU; Tong CH; Packard CJ; Pfeffer MA; Devlin JJ; Shepherd J; Campos H; Sacks FM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):562-7. PubMed ID: 18174457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study.
    Zito F; Lowe GD; Rumley A; McMahon AD; Humphries SE;
    Atherosclerosis; 2002 Nov; 165(1):153-8. PubMed ID: 12208481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
    Circulation; 1998 Apr; 97(15):1440-5. PubMed ID: 9576423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins: cost analysis in Indian scenario from eight major clinical trials.
    Sanmukhani J; Shah V
    J Postgrad Med; 2010; 56(3):196-200. PubMed ID: 20739765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.